VXRT — Vaxart, Inc.
—
OTC ·
Health Care ·
Biotechnology ·
CIK 72444 ·
Last close
$0.35
Market Cap
$86.51M
52W High
$0.84
52W Low
$0.33
ADV30
289,565
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 27,185,000 | — | -13,172,000 | -13,494,000 | 165,185,000 | 50,929,000 | 82,814,000 |
| Mar 2026 | 39,227,000 | — | 5,173,000 | 5,179,000 | 180,055,000 | 50,746,000 | 85,938,000 |
| Dec 2025 | 104,239,000 | — | 55,423,000 | 55,045,000 | 186,079,000 | 53,814,000 | 98,281,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$33,982,000
Investing CF
$-7,225,000
Financing CF
$4,061,000
CapEx
$-601,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.15
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-468,510,000
Inventory
—
Receivables
$46,992,000
ST Investments
$13,047,000
EBIT TTM
$41,205,000
Pretax Income TTM
$39,008,000
Interest Exp TTM
$2,197,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$181,271,008
EBITDA
$35,335,000
Free Cash Flow
$-36,566,248
Enterprise Value
$37,193,752
Total Cash
$65,544,000
Total Debt
$12,568,000
Shares Out
243,700,562
Trailing EPS
$0.17
Book Value
$0.27
ROE
62.4%
ROA
10.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 237,258,000 | 18,074,000 | 16,327,000 | 186,079,000 | 98,281,000 | 87,798,000 | 7,714,000 |
| Dec 2024 | 28,700,000 | -66,293,000 | -66,948,000 | 166,389,000 | 107,464,000 | 58,925,000 | -44,764,000 |
| Dec 2023 | 7,379,000 | -83,347,000 | -82,465,000 | 91,830,000 | 34,025,000 | 57,805,000 | -70,453,000 |
| Dec 2022 | 107,000 | -110,333,000 | -107,758,000 | 153,847,000 | 43,250,000 | 110,597,000 | -94,779,000 |
TTM Snapshot
Revenues TTM
$243,064,000
NetIncome TTM
$38,589,000
OpCashFlow TTM
—
Assets (Latest)
$165,185,000
Forward EPS
$-1.03
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OTLK | Outlook Therapeutics, Inc. | $87.79M | $0.36 | — |
| BDTX | Black Diamond Therapeutics, Inc. | $82.75M | $1.44 | — |
| VYGR | Voyager Therapeutics, Inc. | $94.59M | $1.52 | — |
| CLLS | Cellectis S.A. | $77.08M | $1.06 | — |
| ARMP | Armata Pharmaceuticals, Inc. | $98.93M | $2.66 | — |
News headlines (Yahoo Finance, 1h cache)
Vaxart Q3 Earnings Call Highlights
2026-11-08 23:14 · Yahoo
Vaxart Inc (VXRT) (Q3 2026) Earnings Call Highlights: Cash Runway Into Q2 2027, COVID-19 ...
2026-11-07 05:17 · Yahoo
Vaxart, Inc. Q3 2026 Earnings Call Summary
2026-11-06 13:30 · Yahoo
VAXART, INC. (VXRT) Reports Q3 Loss, Beats Revenue Estimates
2026-11-06 00:00 · Yahoo
Vaxart Provides Business Update and Reports Third Quarter 2026 Financial Results
2026-11-05 21:05 · Yahoo
Vaxart to Host Stockholder Fireside Chat on November 6 at 4:30 p.m. ET
2026-10-29 12:00 · Yahoo
Vaxart Appoints Retired Vice Admiral Raquel C. Bono, M.D., to Board of Directors
2026-10-19 12:00 · Yahoo
Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model
2026-10-08 12:40 · Yahoo
Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference
2026-09-15 06:02 · Yahoo
Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.